CClinicalTrials.gg
CompletedNCT03637452Updated Dec 17, 2020

Baby Albert: Electronic Cigarette Pharmacokinetics (PK) and Abuse Liability

An observational study in Tobacco Use, sponsored by University of Oklahoma. Completed at 1 site in United States. Open to participants aged 18 Years to 99 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-12-17.

Sponsored by University of Oklahoma · Observational

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
19
Ages
18 Years to 99 Years
Sex
All
01

Study summary

The overall aim of the current research is to understand purchasing and product choice behaviors of tobacco/nicotine users if banning the sale of fully nicotinized cigarettes were to go into effect. A sample of up to 30 current cigarette users (n=15) and dual e-cigarette and combustible cigarette users (n=15) who are willing to try an alternative nicotine-delivery device will be recruited. They will complete the screening visit, visit 1 and 2 preceded by 12 hours of nicotine/tobacco abstinent.

Read the detailed description

Participants will be provided information about the study and will provide initial consent for screening via an online screener. Written consent will be completed in person when participants are present to the laboratory. Eligible participants will include anyone over the age of 18 years and those who exclusively use combustible cigarettes or those who dual use e-cigarettes and combustible cigarettes. For the exclusive cigarette group, we will allow some e-cigarette experimentation. Participants will complete three in-lab study visits (1 screener visit and 2 study visits) separated by a standard minimum 48-hour washout period. They will be offered an Uber or other rideshare service as transportation to each study visit, however, they will not be required to use the service.

Participants will complete an in-person screening visit in which they will be rescreened according to the eligibility criteria. Their exhaled carbon monoxide (eCO) will be checked prior to their visits as well as breath alcohol and urine pregnancy (for females) test will be conducted. Participant will also complete baseline assessment measures and Balloon Analog Risk Task (BART)- computerized task measuring impulsivity. At visit 2, participants will complete a standard 10 puff bout with the three e-cigarette devices and their usual brand cigarette. During visit 3, participants will complete three concurrent choice tasks in a counter-balanced fashion.

02

Conditions studied

  • Tobacco Use

Keywords

  • e-cigarettes
  • juul brand e-cigarette
  • njoy brand e-cigarette
  • evolv/mirage DNA 75c brand e-cigarette
03

In context

Lead sponsor

University of Oklahoma is the lead sponsor of 424 studies on the registry; 99 are open to participants now.

Of its 42 completed or terminated interventional studies of FDA-regulated products, 16 (38%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

A sample of up to 30 current cigarette smokers and dual e-cigarette and cigarette users who are willing to use/try an alternative nicotine-delivery device will be recruited via advertisements/ recruitment materials (e.g., craigslist, ads on OSU, OU, and UCO campuses, OUHSC, email) and referrals. Participants will live in the Oklahoma City, OK metro area. Participants will be provided information about the study and provide initial consent for screening via an online screener.

Inclusion criteria

  • be at least 18 years old
  • live within 30 miles of the research site
  • interested in/willing to use an e-cigarette during study visits
  • be willing and able to complete study procedures including specimen collection, survey completion, and remaining nicotine abstinent for 12 hours prior to each study visit
  • speak and understand English
  • willing to provide informed consent
  • bring usual brand cigarettes to screener study visit
  • should have healthy veins

Additional Inclusion criteria for smokers:

  • smoke at least 10 cigarettes per day for the past three months
  • exhaled more than equal to 6 ppm carbon monoxide at the screener visit

Additional Inclusion criteria for dual users:

  • smoke more than equal to 5 tobacco cigarettes per day for the last 3 months
  • use e-cigarettes at least 15 days per month for the last 3 months, and
  • bring e-cigarette device to screener study visit

Exclusion criteria

Exclusion Criteria:

  • currently suffering from lung disease including asthma, cystic fibrosis (CF), or chronic obstructive pulmonary disease (COPD), unless it is well-controlled
  • currently pregnant or breast-feeding or have plans to become pregnant or begin breast-feeding at any point during the study
  • intoxicated at study visits (breath alcohol testing and clean urine drug screen)
  • any known allergies or sensitivity to the known major constituents contained in the aerosol of the study e-cigarette devices (e.g., flavorants, vegetable glycerin, propylene glycol)
  • User of zero-nicotine e-cigarettes
  • history of cardiac event or distress within the past 3 months
  • currently suffering from any blood disorder that includes von willebrand, hemophilia, anemia, sickle cell, leukopenia, thrombocytopenia
  • currently taking an anticoagulant or blood thinning medications
  • have stent, graph, mastectomy or artificial hardware placed in arms or hands (bilaterally)

Additional Exclusion criteria for smokers:

  • have previously used any e-cigarette device (cig-a-like, pen style, mod, APV) for longer than 30 days
  • use of an e-cigarette device over the past 14 days.
05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
19 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Exclusive cigarette smokers

    Exclusive cigarette smokers must smoke at least 10 cigarettes per day for the past three months and have exhaled carbon monoxide (eCO) levels of at least 6 ppm at the screening visit.

  • Dual (Electronic cigarette and cigarette smoking) users

    Dual e-cigarette and cigarette users must have smoked at least 5 cigarettes per day for the last 3 months and use e-cigarettes at least 15 days per month for the last 3 months.

06

What researchers measure

Primary outcomes

  1. Nicotine delivery measured by serum (blood) nicotine

    Participants will complete one standardized puffing bout (10 puffs) with each of the three electronic cigarettes and their usual brand cigarette. Serum nicotine will be measured throughout each standardized puffing bout. Greater levels of serum nicotine will be indicative of greater nicotine delivery.

    Time frame: 1 month

  2. Proportion of puffs earned and allocated to each product in three hypothetical tobacco regulatory scenarios

    Participants will complete three computer tasks simulating hypothetical regulatory scenarios and will earn and allocate puffs to study products. A greater proportion of puffs allocated will indicate greater demand for the product in that hypothetical scenario

    Time frame: 1 month

07

Study locations

1 site
  • University of Oklahoma Health Sciences Center Tobacco Research Center
    Oklahoma City, Oklahoma 73104, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 17, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03637452
Lead sponsor
University of Oklahoma
Responsible party
Sponsor
First posted
Aug 20, 2018
Start date
Nov 12, 2018
Primary completion
May 23, 2019
Completion
May 23, 2019
Last update
Dec 17, 2020

Study contacts

Theodore Wagener, PhD
principal investigator · University of Oklahoma

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion